| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2023 | 19.85% | Goldman Sachs | $33 → $16 | Downgrades | Buy → Neutral |
| 10/25/2023 | 139.7% | Piper Sandler | $33 → $32 | Maintains | Overweight |
| 10/11/2023 | 64.79% | Morgan Stanley | $27 → $22 | Maintains | Equal-Weight |
| 09/21/2023 | 109.74% | Barclays | → $28 | Initiates Coverage On | → Overweight |
| 08/09/2023 | 102.25% | Morgan Stanley | $25 → $27 | Maintains | Equal-Weight |
| 05/08/2023 | 87.27% | Morgan Stanley | $26 → $25 | Maintains | Equal-Weight |
| 03/16/2023 | 147.19% | Raymond James | → $33 | Initiates Coverage On | → Outperform |
| 11/04/2022 | 79.78% | Morgan Stanley | $27 → $24 | Maintains | Equal-Weight |
| 10/14/2022 | 87.27% | B of A Securities | $37 → $25 | Downgrades | Neutral → Underperform |
| 10/12/2022 | 102.25% | Morgan Stanley | $35 → $27 | Maintains | Equal-Weight |
| 09/06/2022 | 154.68% | Piper Sandler | $37 → $34 | Upgrades | Neutral → Overweight |
| 08/05/2022 | 177.15% | B of A Securities | $40 → $37 | Downgrades | Buy → Neutral |
| 07/08/2022 | 154.68% | Morgan Stanley | $35 → $34 | Maintains | Equal-Weight |
| 04/27/2022 | 199.63% | Goldman Sachs | → $40 | Initiates Coverage On | → Buy |
| 04/06/2022 | 162.17% | Morgan Stanley | $37 → $35 | Maintains | Equal-Weight |
| 02/22/2022 | 177.15% | Morgan Stanley | $35 → $37 | Maintains | Equal-Weight |
| 10/07/2021 | 162.17% | Piper Sandler | → $35 | Initiates Coverage On | → Neutral |
| 09/01/2021 | 222.1% | B of A Securities | → $43 | Initiates Coverage On | → Buy |
| 08/16/2021 | 162.17% | Morgan Stanley | $33 → $35 | Maintains | Equal-Weight |
| 07/23/2021 | 162.17% | Citigroup | → $35 | Initiates Coverage On | → Buy |
| 07/22/2021 | 162.17% | Citigroup | → $35 | Initiates Coverage On | → Buy |
| 06/15/2021 | 184.64% | JP Morgan | → $38 | Initiates Coverage On | → Neutral |
| 06/11/2021 | 147.19% | Morgan Stanley | → $33 | Initiates Coverage On | → Equal-Weight |
| 06/10/2021 | — | Evercore ISI Group | Initiates Coverage On | → Outperform |
What is the target price for Organon (OGN)?
The latest price target for Organon (NYSE: OGN) was reported by Goldman Sachs on November 3, 2023. The analyst firm set a price target for $16.00 expecting OGN to rise to within 12 months (a possible 19.85% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Organon (OGN)?
The latest analyst rating for Organon (NYSE: OGN) was provided by Goldman Sachs, and Organon downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for Organon (OGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Organon, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Organon was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
Is the Analyst Rating Organon (OGN) correct?
While ratings are subjective and will change, the latest Organon (OGN) rating was a downgraded with a price target of $33.00 to $16.00. The current price Organon (OGN) is trading at is $13.35, which is out of the analyst's predicted range.